Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) awarded the 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers who displayed exceptional innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar Mantena, a Harvard-MIT M.D.-Ph.D. candidate and Broad Institute nominee. Each received an institutional award of $5,000 and $50,000.

Top U.S. research institutions nominate candidates for the Regeneron Prize to submit “dream projects” in biomedicine. Dr. Hillis from Professor Matthew Vander Heiden’s lab suggested new methods for researching endometriosis. Mr. Mantena, who works under Professor Soumya Raychaudhuri at Brigham and Women’s Hospital, wants to investigate thymic decrease with age using single-cell genomics. Seven other finalists earned $5,000 each. The prize has given out close to $2 million since it was established in 2013. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s broader STEM programs have reached 3.25 million students worldwide since 2020.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.